This study assessed the effects of raloxifene, a selective estrogen receptor modulator (SERM), on ovarian morpholog y and circulating hormone levels in rats. Female Fischer-344 rats (65/group) were given dietary raloxifene for 6 months at average daily doses of 0, 15, 75, and 365 mg/kg. Morphologic evaluation of ovaries was conducted on 25 rats/group at the end of the treatment period and from 20 rats per group after 1 and 3 months withdrawal from treatment. Plasma hormone analyses were conducted on 10 rats per group at the end of the treatment period and after each withdrawal period.
INTRODUCTION
Rodents are susceptible to development of hyperplasia and neoplasia in endocrine target organs when faced with excessive chronic hormonal trophic stimulation. Examples of this phenomenon in rats include thyroid hyperplasia and neoplasia in response to chronic TSH stimulation (6, 22) and development of hyperplasia and neoplasia of gastric enterochromaf n cells associated with excessive chronic gastrin stimulation (12) .
Alterations in endocrine homeostasis are also pivotal in the production of ovarian tumors in rodents, and have been extensively characterized in mice. Transgenic mice which lack functional estrogen receptors (21) or have high luteinizing hormone (LH) (28) or follicle-stimulating hormone (FSH) levels (24) develop hemorrhagic ovarian cysts and granulosa cell tumors. Ovarian tumorigenesis in rodents secondary to disruption of ovarian follicular development is also 719 0192-6233/01$3.00 $0.00 associated with alterations of gonadotropin secretion. Mice with genetically-inherited oocyte depletion demonstrate elevated plasma gonadotropin levels and develop ovarian tumors (26) . Induced causes of disrupted ovarian follicular function associated with ovarian tumorigenesis include irradiation in mice (4) , intrasplenic grafting of ovaries in rats (2) , and treatment with chemical carcinogens in mice (23) . Altered gonadotropin secretion is likely associated with tumorigenesis in these cases also, as evidenced by disruption of estrous cyclicity and absence of later phase follicular development (2, 23) .
Selective estrogen receptor modulators (SERMs), act as estrogen agonists and/or antagonists, depending upon the speci c tissue and species (25) . Raloxifene and tamoxifen are SERMs that have estrogen agonist activities on bone and serum lipid metabolism, and estrogen antagonist activities in mammary tissue in ovariectomized rats (30, 16) . Raloxifene is used clinically to prevent and treat osteoporotic fractures (14) , and tamoxifen is indicated for prevention and treatment of breast cancer (15) .
Chronic treatment of rodents, especially mice, with SERMs has been associated with the development of ovarian tumors. Nine of 25 mice treated with tamoxifen at doses of 5 or 50 mg/kg/day for 15 months developed ovarian granulosa cell adenomas (32) . An increased incidence of ovarian tumors was observed in mice treated for up to 2 years with toremifene at doses of 1 to 30 mg/kg/day (29) . Similarly, mice had an increased incidence of ovarian tumors after 21 months of treatment with 9 to 242 mg/kg/day raloxifene (13) . Raloxifene treatment in mice caused dose-dependent elevations in serum LH levels and changes in ovarian morphology indicative of arrested follicular maturation. These raloxifene-induced changes were reversible upon cessation of treatment (7) .
In a 2-year carcinogenicity study with raloxifene in rats, ovarian neoplasms were increased in incidence in the high dose (259 mg/kg/day) group (13) . The incidence of tumors of granulosa and/or thecal cell origin in this group was 8 of 60 females, compared to 0 or 1 of 60 female rats in the control and lower-dose raloxifene groups. Raloxifene administered to female rats caused cessation of ovarian cyclic activity, as evidenced by changes in vaginal cytology (18) . Upon discontinuation of treatment, receptivity to mating rapidly returned and fertility was not signi cantly affected.
The objective of the current study was to characterize ovarian morphologic changes and associated hormonal alterations, along with their reversibility, in female rats treated with the SERM, raloxifene. Dietary doses were selected to be similar to those used in the 2-year carcinogenicity study; the high dose was the maximum tolerated dose for rats.
MATERIALS AND METHODS
Fischer 344 rats (F344/Ntac), 6 to 7 weeks of age (Taconic Laboratory Animals and Services, Germantown, NY) were allowed to acclimate to caging, feeding and watering conditions for 1 to 2 weeks prior to treatment initiation. Rats were housed individually in ventilated stainless steel cages with wire mesh oors. Environmental conditions were a temperature of 22 4 C, average minimum relative humidity of 50%, and a photoperiod of 12 hours of light and 12 hours of dark, changing at approximately 0600 and 1800 hours. Feed (PMI Certi ed Rodent Diet 5002) and water (Green eld, IN, city water) were provided ad libitum.
Female rats, 65/group were administered diets containing 0%, 0.02%, 0.1%, or 0.5% raloxifene for 6 months. These diets provided average daily raloxifene doses of approximately 0, 15, 75, and 365 mg/kg, respectively. Twentyve rats/group were euthanized at the end of the treatment phase, 20/group after a 1-month reversibility phase (control diet) and 20/group after a 3-month reversibility phase. Rats (10/group/phase) had an indwelling cannula placed in the right atrium, via the external jugular vein, for collection of plasma samples for hormonal analyses. Surgery was performed under iso uorane anesthesia. Blood samples were taken at 0800, 0900, 1000, and 1100 hours and rats were euthanized after the last blood sample. Blood was collected into tubes containing heparin, plasma was obtained by centrifugation, and stored at approximately -70 C until assayed. Individual plasma samples were assayed by radioimmunoassay (RIA) for levels of luteinizing hormone (LH), folliclestimulating hormone (FSH), and prolactin (PRL). Plasma levels of estradiol 17-b (E2) and progesterone (P4) were determined by RIA on plasma samples from individual rats pooled across time points.
Plasma LH and FSH concentrations were determined according to the double antibody method modi ed from Niswender et al (27) . These assays were conducted using rabbit anti-rat LH or rabbit anti-rat FSH primary antibody, rat LH (RP-3) or rat FSH (RP-2) as the reference standards (obtained from A. F. Parlow, Harbor-UCLA Medical Center, Torrance, CA), iodinated rLH or rFSH (Covance Laboratories Inc, Vienna, VA) and goat anti-rabbit secondary antibody (Antibodies Inc, Davis, CA). The LH assay had a working range of 0.01 to 1.0 ng/tube. The FSH assay had a working range of 0.05 to 5.0 ng/tube. Plasma prolactin concentrations were determined according to the homologous double antibody methods using the rabbit anti-rat PRL primary antibody, rat PRL (RP-3) reference standard, iodinated rPRL, and goat anti-rabbit secondary antibody (suppliers as previously described). The PRL assay had a working range of 0.025 to 5.0 ng/tube. Results from these assays were calculated and reported as ng/mL. Plasma E2 was determined by RIA using the DiaSorin clinical assay kit (Sorin Diagnostics s.r.l., Saluggia, Italy). The working range of the assay was 0.05 to 5.0 pg/tube. The limit of detection of the assay was 5 pg/mL. Results from the assay were calculated and reported as pg/mL. Plasma P4 was determined by RIA using the DPC Coat-A-Count kit (Diagnostics Products Corp, Los Angeles, CA). The working range of the assay was 0.01 to 4.0 ng/tube. Results from the assay were calculated and reported as ng/mL.
Homogeneity of variances was determined in individual hormone data sets using Levene's test (20) at the 0.05 level. Data sets with a signi cant lack of homogeneity of variance were rank-average transformed prior to further statistical analysis. Quantitative results for individual hormones during treatment and reversibility phases were analyzed separately using a Dunnett's test (11) comparing means to control for each treatment at the individual time points, tested at the 0.05 signi cance level.
Ovaries were taken from each rat for morphologic evaluation. Ovaries were collected and preserved in 10% neutral buffered formalin, embedded intact in paraf n, sectioned to approximately the midportion of the ovary, stained with hematoxylin and eosin, and examined microscopically.
RESULTS

Hormone Analyses
Treatment with raloxifene caused signi cant increases in circulating levels of LH and E2 and decreases in levels of P4. With the exception of a few individual animals, these alterations were reversed after 1 month on control diet.
At the end of the treatment phase, LH was increased in the mid-and high-dose groups at all time points ( Figure 1) . Although there was a tendency for LH levels in the low-dose group to be greater than those in controls, this difference was signi cant only at the 0900-hour time point. There were no signi cant differences in LH levels in treated compared to control rats, at the end of either reversal period (Figure 2 , 3-month reversal data shown).
Treatment with raloxifene produced a dose-responsive increase in circulating levels of E2 ( Figure 3 ). Progesterone levels at the end of the treatment period were decreased in a nondose-dependent manner in all treated groups (Figure 4 ). At the end of 1-month and 3-month reversibility phases, levels of E2 and P4 were generally comparable in raloxifene treated and control groups (Figures 3 and 4) , with the exception of 4 individuals. Two low-dose rats after one month of reversibility and one low-dose rat after 3 months of reversibility had no detectable levels of either E2 or P4. A high-dose rat after 3 months of reversibility had abnormally high levels of E2 (82.99 pg/ml). P4 for this rat (9.21 ng/ml) was within the normal range for rats with corpora lutea (CL), but this rat had a granulosa cell tumor and no observable CL (described later).
There was no effect of treatment with raloxifene on circulating levels of FSH (data not shown). Although statistically signi cant decreases in PRL levels were noted at several time points in raloxifene-treated groups (data not shown), the PRL levels remained within the normal range of basal secretion (3-40 ng/ml). The high-dose rat that had high levels of E2 at the end of the 3-month reversibility period was hyperprolactinemic, with prolactin levels in excess of 500 ng/ml.
Ovarian Morphology
Ovaries from all raloxifene-treated rats after 6 months of treatment lacked the morphologic characteristics of cyclic variation present among the controls. Changes in ovaries of most treated rats were not progressive with dose and included follicular prominence and absence of CL and many had focal intrafollicular hyperplasia of granulosa cells (Table 1 and Figure 5 ). Follicular prominence was consistent with retention of anovulatory follicles and was characterized by multiple large, slightly dilated antral follicles that were lined by an orderly layer of often attenuated, normal-to-degenerate granulosa cells ( Figure 5 ). A few dilated follicles contained oocyte cross sections, and many of these oocytes were degenerative. Granulosa cell hyperplasia in many rats was limited to a minimal to slight change within individual follicles ( Figures 5 and 6 ). This intrafollicular granulosa cell hyperplasia was typically seen in antral, often slightly dilated follicles. Affected follicles had papillary infoldings of granulosa cells into the follicular lumen with subjacent infoldings of thecal cells that were often associated with a vascular bud ( Figure 6 ).
Less commonly, rete peg-like proliferations of granulosa cells extended into the ovarian stroma away from the follicular lumen. A few treated rats in the mid-and high-dose groups (2 of 25 and 3 of 25, respectively) each had a more extensive focal proliferation of granulosa cells, termed cystic granulosa cell hyperplasia. These foci were approximately 3 to 6 mm in overall size and were characterized by moderate papillary proliferations of large, normal appearing granulosa cells associated with cystic spaces (Figures 7 and 8) . The moderate to marked cysts were often multiple or multilocular, were lined by an attenuated layer of cells and contained eosinophilic proteinaceous material that was often admixed with blood. The cystic granulosa cell hyperplasia was neither compressive nor invasive. Four of the 5 rats with cystic granulosa cell hyperplasia also had inactive ovaries, characterized by lack of antral follicles and an absence of CL. The fth rat with cystic granulosa cell hyperplasia had follicular prominence similar to that present in other rats in the treatment groups.
Most treated rats had an absence of CL. One low-dose rat had persistence of a few older, eosinophilic CL, without the normal concurrent younger (basophilic) CL, a change termed depleted CL. Most treated rats had luteinization of interstitial glands. This was characterized by increased eosinophilia and decreased intracytoplasmic vacuolation of interstitial cells compared to those of controls. A total of 5 rats in the midand high-dose groups also had ovarian cysts. These cysts usually were single, most likely follicular in origin, lined by attenuated cells and contained eosinophilic proteinaceous material.
After 1 month of drug withdrawal, most previously treated rats had evidence of ovarian cyclic changes, including developing follicles and various stages of CL ( Table 2 ). The exceptions to this were 4 low-dose group rats that had follicular prominence accompanied by an absence of CL. In contrast to the treatment phase, luteinization of interstitial glands was not a prominent feature in these rats. Intrafollicular granulosa cell hyperplasia was not seen in rats after 1 month of reversibility. Cystic granulosa cell hyperplasia was seen in only 1 animal (mid-dose group), and in this animal the hyperplastic granulosa cells were surrounded and in ltrated by increased amounts of collagenous connective tissue. Other rats in the mid-and high-dose groups had focal sclerotic lesions, approximately 1 to 3 mm in overall size, characterized by dense collagenous connective tissue, often admixed with hemosiderin-laden macrophages (Figure 9 ). In some, the sclerotic foci were associated with a prominent cystic space lled with pale eosinophilic material or blood. Previously treated rats also had an increased incidence of vacuolation of CL, interstitial glands, or unde ned areas of the ovary. Vacuolation of CL was characterized by aggregates of large, lipid-like vacuoles, distinct from the ner, lacy vacuolar changes normally seen in mature CL. Ovarian cysts and cystic CL were also more numerous in treated rats compared to control rats.
Ovaries from raloxifene-treated rats after 3 months of reversibility were generally similar to those after 1 month of reversibility. All previously treated rats except one had morphologic evidence of ovarian cyclicity ( Table 3 ). The exception was a low-dose rat that had follicular prominence and absence of CL. Sclerotic foci were present in 1 to 3 rats in each raloxifene-treated group but were not cystic like those present after 1 month. Vacuolation of CL was present in a dose-related incidence, but cystic change in CL was not. One high-dose rat had a granulosa cell tumor, characterized by proliferative granulosa cells, usually in papillary formations and cords, and cystic spaces. This lesion was approximately 12-13 mm in overall diameter, and effaced the affected ovary ( Figure 10 ). The opposite ovary was atrophied. 
DISCUSSION
In the present study, treatment of Fischer-344 rats with the selective estrogen receptor, raloxifene, caused reversible alterations of gonadotropin secretion, retention of anovulatory ovarian follicles, and granulosa cell hyperplasia in the ovaries. Raloxifene, which binds to the estrogen receptor (34) , may block estrogen feedback to the hypothalamuspituitary axis, resulting in loss of the preovulatory LH surge and sustained increase in circulating LH levels, which was evident in the mid-and high-dose groups in the current study. Estrogen receptor-a knock-out (ERKO) mice have a genetic deletion of the estrogen receptor and resultant increased pituitary expression of LH mRNA and high serum LH levels (19, 31) . When gonadatropins are present at sustained levels, their physiologi c role in regulating ovarian growth and development is prolonged, resulting in morphologic changes in the ovary. Transgenic mice with high gonadatropin levels (19, 21, 28) have morphologic changes in the ovary similar to those observed in raloxifene treated mice (7) . These changes included fewer corpora lutea and a prominence of follicles in varying stages of maturity and degeneration. The apparent arrest of development of antral follicles, hyperplasia of granulosa cells, and luteinization of interstitial glands in raloxifene-treated rats are all consistent with the elevated LH levels.
Granulosa cell hyperplasia in the ovaries of raloxifenetreated rats was usually intrafollicular, with proliferation of otherwise morphologically normal granulosa cells within individual antral follicles. More advanced focal granulosa cell hyperplasia was limited to the mid-and high-dose groups and was associated with cystic spaces beyond the size of a single follicle. In most animals with cystic granulosa cell hyperplasia, both the affected and contralateral ovaries were inactive, suggesting additional endocrine disruption. The doseresponsive increases in plasma E2 levels associated with raloxifene-treatment were likely in response to the increased circulating levels of LH and may have been secondary to the follicular prominence and/or granulosa cell hyperplasia. Rats treated at the low-and mid-doses had levels of E2 normally seen only on the morning of proestrus, whereas plasma levels of E2 in the high-dose group exceeded values seen at any time during normal estrous cycles. In spite of this, the high levels of E2 were insuf cient to overcome the disruption of the hypothalamic-pituitary-ovarian axis induced by raloxifene.
Most raloxifene-treated rats observed after 1 month of reversibility had morphologic evidence of ovarian cyclic activity and had a normalization of plasma levels of LH, E2 and P4. A few low-dose rats during both the 1-and 3-month reversibility periods apparently had not returned to normal ovarian cycling, as their ovaries retained the follicular prominence and had an absence of CL similar to changes seen at the end of the treatment phase. These rats had undetectable levels of P4, consistent with the lack of CL. However, these rats also had undetectable levels of E2 and basal levels of LH, suggesting that at least some of the underlying hormonal changes had been reversed but that the ovaries had not been suf ciently stimulated to resume cyclic activity.
In a previous 2-year study in rats, treatment of female rats with dietary raloxifene equivalent to an average daily dose of 259 mg/kg resulted in an increased incidence of ovarian neoplasms. The ovarian neoplasms were of granulosa and/or thecal cell origin and occurred in 8 of 60 female rats in that dose group compared to 0 or 1 of 60 in controls or rats given lower doses (10.4 or 51 mg/kg/day) of raloxifene (13) . The incidence (13%) of ovarian neoplasms in the high-dose group in the 2-year study is similar to the incidence (12%) of focal cystic granulosa cell hyperplasia in the high-dose group of the current study after 6 months of treatment. This suggests that the proliferative lesions have a very low rate of progression or a relatively high rate of spontaneous regression.
After 1 month of reversibility, only 1 animal had evidence of focal cystic granulosa cell hyperplasia, and this lesion appeared to be regressing. Focal sclerotic lesions in the ovaries, presumably foci of regression of cystic granulosa cell hyperplasia, were present in 25% of the rats examined after 1 month of reversibility and in 10% of the rats after 3 months of reversibility. After compound withdrawal, only 1 rat had a proliferative lesion that continued to develop. This persistent proliferative lesion was associated with effacement of the pre-existent ovarian tissue and marked increases in plasma concentrations of PRL, E2, and P4, and was diagnosed as a granulosa cell tumor. Reversibility of hormonally mediated hyperplastic and neoplastic-like lesions following reestablishment of a normal endocrine state has been seen in other rat endocrine tissues, such as the thyroid gland (1). This suggests that although these hormonally mediated hyperplastic granulosa cell lesions can be morphologically consistent with benign neoplastic transformation, they are not necessarily autonomous, as most of these lesions regress when hormonal support is removed.
Differentiation between granulosa cell hyperplasia and benign granulosa cell tumors is dif cult because the granulosa cells in both cases are monomorphic, and size of the lesion has been used as a differentiating feature. Diagnostic criteria for granulosa cell tumors in rats suggest that a size of 2-3 mm be used as a cut-off between focal hyperplastic lesions and granulosa cell tumors (10) . However, in the current study, the focal cystic granulosa cell proliferative lesions had an overall size, including cystic space, of approximately 3 to 6 mm. Because these lesions were reversible when treatment was discontinued, they were considered to be hyperplastic lesions. Atrophy of ovarian tissue, suggestive of additional hormonal changes, was also seen with these reversible lesions, hence was not a criterion for differentiating between hyperplasia and neoplasia. The only granulosa cell proliferative lesion that persisted through the 3-month reversibility period had an overall diameter of approximately 12 to 13 mm and effaced the ovary. This indicates that a cut-off size for focal granulosa cell hyperplasia vs granulosa cell tumor is between 6 and 12 mm and that effacement of the ovary could also be a criterion for neoplasia.
Although hormonal imbalances in rodents have been shown to alter ovarian morphology and function and are correlated with an increased incidence of ovarian neoplasia, these preclinical models are not predictive of ovarian cancer in women (1, 5, 9) . To date, there is no correlation between the occurrence of ovarian cancer in women and increased serum gonadotropin levels. In fact, women with a personal or family history of ovarian cancer have signi cantly lower serum LH concentrations than women without such a history (3, 8, 17, 33) . Thus, the relationship between elevated circulating gonadotropin levels and an increased incidence of ovarian tumors in rodents does not appear to be true in humans.
The results of this study indicate that raloxifene administration to Fischer-344 rats causes increases in plasma LH levels, alterations in ovarian morphology consistent with ovulatory arrest, and granulosa cell hyperplasia. The proliferation of ovarian granulosa cells in response to chronic hormonal stimulation was similar to changes induced in other endocrine target organs in rats in response to chronic excessive stimulation with trophic hormones. Many of these proliferative changes, including some with features typical of benign neoplasms, are reversible upon cessation of hormonal stimulation. However, a small subset of the proliferative lesions develop into autonomous neoplastic lesions.
